{"schema_version":"secwatch.filing_event.v1","accession":"0000896264-26-000005","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.984825+00:00","generated_at":"2026-05-16T11:00:11.843020+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"USANA prelim FY2025 sales ~$925M (beat guidance); FY2026 guidance $925M-$1B","bullets":["Preliminary FY2025 net sales of ~$925M, above prior guidance of ~$920M.","FY2026 net sales guidance of $925M-$1.0B; core USANA nutritional seen at $720-765M (down from ~$777M).","Hiya segment guided $140-155M (up from ~$132M); Rise Wellness $65-80M (up from ~$16M).","FY2026 is a 52-week year (one week less than FY2025), impacting core business comparison.","Rise Wellness margins expected at breakeven in FY2026 due to growth investments; working capital rising at both Hiya and Rise."],"urls":{"canonical":"https://secwatch.observer/filing/0000896264-26-000005","json":"https://secwatch.observer/filing/0000896264-26-000005.json","markdown":"https://secwatch.observer/filing/0000896264-26-000005.md","text":"https://secwatch.observer/filing/0000896264-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000089626426000005/0000896264-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000089626426000005/usna-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:00:11.843020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}